tbuckley/cabot-search huggingface dataset:
P132 Health care utilisation and costs among COPD patients newly prescribed maintenance therapy in the United Kingdom (UK): Abstract P132 Table 1
Authors: Y Punekar, SH Landis, K Bonar, H Le
Journal: Thorax (2015)

<h3>Aim</h3> To characterise disease burden, health care resource utilisation (HCRU), and costs among a cohort of COPD patients newly prescribed maintenance therapy in UK general practice. <h3>Method</h3> A retrospective cohort of COPD patients aged ≥40 yrs and newly prescribed COPD monotherapy (long acting beta-agonists [LABA] or long acting muscarinic antagonist [LAMA]), dual therapy (LABA+LAMA; LABA+inhaled corticosteroid (ICS); LAMA+ICS) or open triple therapy (LAMA+LABA+ICS) between 1/1/2009 and 30/11/2012 was identified from UK Clinical Practice Research Datalink (CPRD). Health care resource utilisation assessed in the 12 months prior to maintenance therapy initiation included moderate (community treated) and severe (hospital or A&amp;E treated) COPD exacerbations (rate per 100 person years [PY]), general practice (GP) interactions, other COPD treatments, and non-COPD related hospitalisations. The costs associated with HCRU were calculated using National Health Services reference costs for 2013–14 and PSSRU costs for 2014. <h3>Results</h3> A total of 39,639 COPD patients were included (54% male, mean age 68 yrs (SD: 11)). LABA+ICS (39%) and LAMA (34%) were the most commonly initiated LABD; 13% were first exposed to LABD as part of an open triple regimen (Table 1). Patients initiating an ICS-containing regimen had a higher exacerbation rate (moderate or severe) in the 12 months prior to maintenance therapy initiation (LABA+ICS: 0.74 per PY [95% CI:0.72–0.75]; LAMA+ICS: 0.86 per PY [0.82–0.90] and LAMA+LABA+ICS: 0.83 per PY [0.80–0.85]) compared to patients on bronchodilators alone (LAMA: 0.55 per PY [0.54–0.57]; LABA: 0.56 per PY [0.54–0.59]; LAMA+LABA: 0.50 per PY [0.44–0.56]). Patients on open triple therapy demonstrated the highest rates of non-COPD related hospitalisations. The annual per patient cost ranged from £2,139 (LABA) to £2,876 (LAMA+LABA+ICS); approximately half were due to GP visits and a third resulted from non-COPD related hospitalisations (Table 1). <h3>Conclusion</h3> Patients with a higher baseline exacerbation rate were more likely to receive ICS- containing therapies compared to those taking bronchodilators alone. Across all maintenance therapy groups, GP visits and non-COPD related hospitalisations were the primary driver of total costs.
Active Bacterial Core Surveillance for Legionellosis — United States, 2011–2013
Authors: Kathleen L. Dooling, Karrie-Ann Toews, Lauri A. Hicks, Laurel E. Garrison, Brian Bachaus, Shelley Zansky, L. Rand Carpenter, Bill Schaffner, Erin Parker, Susan Petit, Ann Thomas, Stephanie Thomas, Robert Mansmann, Craig Morin, Benjamin White, Gayle E. Langley
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

During 2000–2011, passive surveillance for legionellosis in the United States demonstrated a 249% increase in crude incidence, although little was known about the clinical course and method of diagnosis. In 2011, a system of active, population-based surveillance for legionellosis was instituted through CDC’s Active Bacterial Core surveillance (ABCs) program. Overall disease rates were similar in both the passive and active systems, but more complete demographic information and additional clinical and laboratory data were only available from ABCs. ABCs data during 2011–2013 showed that approximately 44% of patients with legionellosis required intensive care, and 9% died. Disease incidence was higher among blacks than whites and was 10 times higher in New York than California. Laboratory data indicated a reliance on urinary antigen testing, which only detects Legionella pneumophila serogroup 1 (Lp1). ABCs data highlight the severity of the disease, the need to better understand racial and regional differences, and the need for better diagnostic testing to detect infections.
Allergen endotoxins induce T-cell–dependent and non–IgE-mediated nasal hypersensitivity in mice
Authors: Naruhito Iwasaki, Kazufumi Matsushita, Ayumi Fukuoka, Masakiyo Nakahira, Makoto Matsumoto, Shoko Akasaki, Koubun Yasuda, Takeshi Shimizu, Tomohiro Yoshimoto
Journal: Journal of Allergy and Clinical Immunology (2016)
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Authors: Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research (2016)

Genotype-directed therapy is the standard of care for advanced non-small cell lung cancer (NSCLC), but obtaining tumor tissue for genotyping remains a challenge. Circulating tumor cell (CTC) or cell-free DNA (cfDNA) analysis may allow for noninvasive evaluation. This prospective trial evaluated CTCs and cfDNA in EGFR-mutant NSCLC patients treated with erlotinib until progression.EGFR-mutant NSCLC patients were enrolled in a phase II trial of erlotinib. Blood was collected at baseline, every 2 months on study, and at disease progression. Plasma genotyping was performed by droplet digital PCR for EGFR19del, L858R, and T790M. CTCs were isolated by CellSave, enumerated, and analyzed by immunofluorescence for CD45 and pan-cytokeratin and EGFR and MET FISH were also performed. Rebiopsy was performed at disease progression.Sixty patients were enrolled; 44 patients discontinued therapy for disease progression. Rebiopsy occurred in 35 of 44 patients (80%), with paired CTC/cfDNA analysis in 41 of 44 samples at baseline and 36 of 44 samples at progression. T790M was identified in 23 of 35 (66%) tissue biopsies and 9 of 39 (23%) cfDNA samples. CTC analysis at progression identified MET amplification in 3 samples in which tissue analysis could not be performed. cfDNA analysis identified T790M in 2 samples in which rebiopsy was not possible. At diagnosis, high levels of cfDNA but not high levels of CTCs correlated with progression-free survival.cfDNA and CTCs are complementary, noninvasive assays for evaluation of acquired resistance to first-line EGFR TKIs and may expand the number of patients in whom actionable genetic information can be obtained at acquired resistance. Serial cfDNA monitoring may offer greater clinical utility than serial monitoring of CTCs. Clin Cancer Res; 22(24); 6010-20. ©2016 AACR.
Malaria surveillance in Italy: 1997 analysis and 1998 provisional data
Authors: R Romi, D Boccolini, G Majori
Journal: Eurosurveillance (1999)

Malaria is the commonest imported infectious disease in Italy. Malaria was endemic throughout much of the country until it was eradicated nearly 50 years ago. Since then, a malaria surveillance system has been set up to detect locally acquired cases that
Psychopathology and mental retardation: A study of 100 mentally retarded children: I. Psychopathology
Authors: I Philips, N Williams
Journal: American Journal of Psychiatry (1975)

The authors studied 100 mentally retarded children referred to a psychiatric clinic in regard to the severity of their retardation, their ages at the time of referral, their social class, their presenting symptoms and diagnoses, and the effects of organicity on their clinical pictures. They found that 38 of these children were psychotically disturbed, 13 had no evidence of psychiatric disorder, and 49 showed symptoms of characterologic, neurotic, behavioral, or situational disorders. Although the incidence of emotional disorder was high among these children, their symptoms did not differ in kind from those found in a group of nonretarded children referred to the clinic.
Thyroid Carcinoma in Children
Authors: T WINSHIP, W W CHASE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Worsening Stroke Symptoms in an 80-Year-Old Man
Authors: Megan G. Hofmeister, Angela Dao, April M. Young
Journal: JAMA Neurology (2016)

An 80-year-old man presented to the hospital with new-onset slurred speech and left-sided facial droop. Magnetic resonance imaging scans of the head were visually interpreted to show an acute infarct involving the posterior right frontal lobe. What is your diagnosis?
Abstract A2-22: Mitochondrial dysfunction induces cancer stem-like phenotypes in Hep3B hepatocellular carcinoma cell line
Authors: Yu-Seon Han, Eui-Yeun Yi, Yung-Jin Kim
Journal: Cancer Research (2015)

Abstract Cancer stem cells (CSCs) are a small population of cancer cells that possess characteristics associated with normal stem cells such as self-renewal and differentiation into multiple cell types. Additionally, CSCs have been reported to relationship on tumor relapse after cancer therapy. Mitochondrial dysfunction (MD) has also been known to be associated with cancer malignancy. In this report, the relation of MD and CSCs were initially investigated using mitochondrial-depleted rho0 cells derived from Hep3B hepatocellular carcinoma cell line. The Hep3B/rho0 cells showed cancer stem-like phenotypes including tumor initiation, tumor malignancy, stem cell-related signaling, chemotherapies and radiotherapy resistance. These results suggest that mitochondrial dysfunction induces cancer stem-like phenotypes. Taken together, mitochondrial dysfunction plays an important role in the acquisition of cancer stem-like phenotypes and could be a novel therapeutic target to cancer therapy. Citation Format: Yu-Seon Han, Eui-Yeun Yi, Yung-Jin Kim. Mitochondrial dysfunction induces cancer stem-like phenotypes in Hep3B hepatocellular carcinoma cell line. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A2-22.
THU0564 Is Extrathoracic Disease Associated with Mortality in Sarcoidosis? Predicting Survival According to the Epidemiological and Clinical Features at Diagnosis in 170 Patients
Authors: P. Brito Zeron, J. Sellarés, X. Bosch, F. Hernández, C. Lopez-Casany, M. Sanchez, J. Ramírez, H. Gheitasi, B. Kostov, J. Santos, A. Sisό Almirall, C. Agustí, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To evaluate extrapulmonary activity and correlate baseline features at diagnosis with survival in a large cohort of patients with sarcoidosis. <h3>Methods</h3> We studied 170 patients consecutively diagnosed with sarcoidosis in the last 10 years. The diagnosis of sarcoidosis was based on clinical criteria and imaging studies, together with the histopathological demonstration of non-necrotizing granulomas, and the exclusion of other granulomatous diseases, especially infections (tuberculosis). Extrapulmonary involvement was defined according to the criteria defined by Judson et al, 2011. <h3>Results</h3> There were 111 (65%) women and 59 (35%) men, with a mean age at diagnosis of 47.49 years (range 17-92). The main clinical manifestations present at diagnosis were respiratory symptoms in 112 (66%) patients, erythema nodosum in 35 (21%), articular involvement in 35 (21%) and fever in 34 (20%) patients; incidental imaging findings in asymptomatic patients was found in 12% of cases. After a mean follow-up of 107.4 months, 21 (12%) patients died. The main causes of death were infections in 4 patients, cardiovascular disease in 2, pulmonary sarcoidosis in 1, neoplasia in 1 and other causes in 2 patients; in the remaining 11 patients, the cause of death was unknown or unclassifiable. Survivors had a lower mean age (44.82 yrs. vs. 65.95 yrs. p&lt;0.001) and a statistical trend to higher mean levels of serum angiotensin-converting enzyme (ACE) (105.78 U/L vs. 64.58 U/L, p=0.16). The mortality rate was higher in patients born in Spain (16% vs. 0% in those born outside Spain, p=0.008). Extrapulmonary involvement was unrelated to death (mortality rate of 11% vs. 14% in patients with pulmonary involvement). Multivariate analysis identified mean age at diagnosis (p&lt;0.001) as an independent risk factor associated with death. <h3>Conclusions</h3> Extrapulmonary involvement in sarcoidosis is not associated with mortality. An older age at diagnosis was the principal risk factor associated with death, while patients born outside Spain had a lower mortality rate, and mean ACE levels at diagnosis were inversely associated with survival. The very-low rate of deaths caused directly by sarcoidosis might explain our results. <h3>Disclosure of Interest</h3> None declared
Massachusetts Medical Society
Authors: Everett R. Spencer
Journal: New England Journal of Medicine (1981)

In May 1956, the Massachusetts Medical Society observed its 175th anniversary by noting the occasion briefly on the inside cover of a program for a three-day scientific meeting. Titled Eight Score and Fifteen Years, the unsigned* acknowledgement concluded:Few professional or lay organizations in this young country can boast of 175 years of active, continuous existence. Admittedly it is a record of which to be proud. Some may even say that the 175th Anniversary is a just cause for a celebration of sorts. The Society's current officers, however, in reflecting on the record of achievements of the Society and . . .
Gonadotrophins and Ovarian Cancer Risk
Authors: Janet Mohle, Alice Whittemore, Malcolm Pike, Sarah Darby
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Gonadotrophins and Ovarian Cancer Risk Get access Janet Mohle, Janet Mohle Imperial Cancer Research Fund Cancer Epidemiology and Clinical Trials Unit University of Oxford, Oxford OX2 6HE, United Kingdom Search for other works by this author on: Oxford Academic PubMed Google Scholar Alice Whittemore, Alice Whittemore Imperial Cancer Research Fund Cancer Epidemiology and Clinical Trials Unit University of Oxford, Oxford OX2 6HE, United Kingdom Search for other works by this author on: Oxford Academic PubMed Google Scholar Malcolm Pike, Malcolm Pike Imperial Cancer Research Fund Cancer Epidemiology and Clinical Trials Unit University of Oxford, Oxford OX2 6HE, United Kingdom Search for other works by this author on: Oxford Academic PubMed Google Scholar Sarah Darby Sarah Darby Imperial Cancer Research Fund Cancer Epidemiology and Clinical Trials Unit University of Oxford, Oxford OX2 6HE, United Kingdom Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 75, Issue 1, July 1985, Pages 178–179, https://doi.org/10.1093/jnci/75.1.178 Published: 01 July 1985
SAT0088 Prognostic Factors Toward Rapid Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving Treat to Target Strategy
Authors: T. Koga, A. Okada, A. Kawakami, T. Fukuda, T. Hidaka, T. Ishii, Y. Ueki, T. Kodera, M. Nakashima, Y. Takahashi, S. Honda, R. Watanabe, H. Okuno, M. Tamai, K. Aoyagi, K. Eguchi
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease-modifying antirheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). Their effects are supposed to be different according to clinical condition, however, there have been few epidemiological reports of longitudinal investigation in RA patients captured in daily practice. <h3>Objectives</h3> To determine prognostic factors of radiographic progression (RRP) in patients with RA in clinical practice for achieving treat to target strategy. <h3>Methods</h3> We performed a Japanese multicenter prospective study on biological DMARDs (bDMARDs)-naïve 887 RA patients with moderate to high disease activity or with radiographic bone erosion, treated with conventional synthetic DMARDs (csDMARDs) at study entry. We observed longitudinally these patients for 1 year and assessed Disease Activity Score in 28 joint (DAS28-ESR) every 3 months. RRP was defined as yearly progression of modified total Sharp score (mTSS) &gt;3.0U. Furthermore, we divided into two groups based on disease duration (&lt;3 years or 3 ≥ years) and examined for subgroup analysis. <h3>Results</h3> RRP was found in 9.2% of patients. Multiple step-wise regression analysis revealed that disease duration (OR=0.92, 95% CI 0.86 to 0.99), time-integrated DAS28-ESR during 1 year (OR=1.04, 95% CI 1.01 to 1.06), CRP at baseline (OR=1.24, 95% CI 1.07 to 1.43), and introduction of bDMARDs (OR=0.12, 95% CI 0.03 to 0.55) are independent variables to predict the development of RRP. Intriguingly, our subgroup analysis has revealed that time-integrated DAS28-ESR during 1 year is not a significant predictor for RRP in early RA and the protective effect of bDMARDs toward RRP is evident in early RA patients. <h3>Conclusions</h3> RRP in RA patients treated with DMARDs is closely associated with persistent disease activity or early introduction of bDMARDs. Among early RA patient, subclinical RRP should be considered regardless of integrated disease activity. <h3>Disclosure of Interest</h3> None declared
Book: Scotland's Health and Health Services
Authors: Bryan Christie
Journal: BMJ (2003)

There is something going on in Scotland that is almost unique in the developed world. It has nothing to do with misty glens, fiery alcoholic drinks, or skirling pipe music. It has to do with population decline. In 2001 there were 5000 more deaths in Scotland than there were births. The population peaked in the mid-1970s and has been declining slowly ever since.​since.




Figure 1



Eds Kevin Woods, David Carter

The Nuffield Trust, £28.50, pp 328 ISBN 0 11 7032417

Rating: ★★




By 2021 there will be 20% fewer teenagers and 25% more people aged over 60. This is going to have major implications for the way health services will be provided. At a time when more and more elderly people will be needing care, the pool of people who can provide it will be shrinking.

This book provides a timely warning that action needs to be taken now to assess the implications of this and other changes, such as developments in genetics. It makes the case for the establishment of a long term planning organisation to ensure that Scotland anticipates rather than ends up being ambushed by future events. Planning may be an unfashionable term in today's health service but it is needed to counterbalance the short term politically driven objectives of the NHS, argues the book's final chapter.

The authors are certainly people who should know. They include many of the leaders of the Scottish health service. The two editors, Professor Kevin Woods and Sir David Carter, also helped to shape the service when they were respectively the health department's director of strategy and performance management and its chief medical officer.

They have produced a comprehensive account of developments in the Scottish health service over the past 20 years. One of the most interesting aspects is the differences that are becoming increasingly apparent between Scotland and the rest of the United Kingdom. As England has pursued star ratings, foundation hospitals, and a greater role for the private sector, Scotland has remained loyal to traditional health services. It is placing its faith in a more collaborative approach such as the development of managed clinical networks, which are starting to deliver improvements in cancer and other services. It will be interesting to see which set of reforms has the greatest impact.

Yet the book is not entirely a success. The authors of the 12 chapters have been allowed to develop their own approach and some have chosen to provide a detailed record of events while others are more analytical. The result is an uneven publication that would have benefited from a heavier editorial hand. It remains, however, a useful contribution to explain what happened to Scotland's health and health services in the last years of the 20th century. It also makes some important suggestions on the priorities that need to be addressed in the new century.
Characteristics of Heterologous Membrane Antigen on Cultured Human Cells&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: R F Irie, K Irie, D L Morton
Journal: JNCI Journal of the National Cancer Institute (1974)

HM Ag (heterologous membrane antigen) is incorporated into membranes of cultured human cells grown in media containing bovine serum. Natural antibody against HM Ag isfound in human sera. Immune adherence tests assayed the HM Ag on a human sarcoma cell line (SA-2). HM Ag was removed from the cell membranes of SA-2 grown in media with fetal calf serum (FCS) after the cells were transferred into agamma human serum (2-3 wk) or into whole human serum (1-2 wk). Cells grown in human serum reincorporated HM Ag into their membranes within 24 hours after transfer to medium with 20% FCS. The incorporation did not occur at 0° C and was suppressed with metabolic inhibitors. Treatment with neuraminidase removed the antigen, though treatment with proteinase did not. Anti-HL-A antibody reactivity was higher to cells grown with agamma human serum than to cells grown with FCS.
THE RURAL LABORATORY.
Authors: R GORY
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal